OTCMKTS:ATRX Adhera Therapeutics - ATRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.55 0.00 (0.00%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.55▼$0.5550-Day Range$0.43▼$0.9552-Week Range$0.43▼$3.00Volume1 shsAverage Volume2,908 shsMarket Capitalization$1.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest About Adhera Therapeutics (OTCMKTS:ATRX) StockAdhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Read More Receive ATRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRX Stock News HeadlinesFebruary 27, 2023 | finance.yahoo.comAdhera Therapeutics, Inc. (ATRX)January 25, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesMarch 24, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!January 18, 2023 | seekingalpha.comCGTX Cognition Therapeutics, Inc.December 5, 2022 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringOctober 9, 2022 | benzinga.comAdhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, PredictionsSeptember 21, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior...September 19, 2022 | finance.yahoo.comAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistMarch 24, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 19, 2022 | seekingalpha.comAdhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplistJuly 19, 2022 | finance.yahoo.comAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinMay 19, 2022 | seekingalpha.comAdhera Therapeutics appoints new Chairman of the Board, focuses on uplist to NasdaqMay 19, 2022 | finance.yahoo.comAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQJanuary 20, 2022 | finance.yahoo.comAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceNovember 22, 2021 | finance.yahoo.comAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersNovember 8, 2021 | finance.yahoo.comAdhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of DirectorsOctober 20, 2021 | finance.yahoo.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target IndicationsOctober 15, 2021 | finance.yahoo.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s DiseaseOctober 4, 2021 | finance.yahoo.comAdhera Receives European Patent Covering MLR-1019 and Derivatives for Treating DyskinesiasSeptember 13, 2021 | finance.yahoo.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsSeptember 9, 2021 | finance.yahoo.comAdhera Therapeutics Appoints Dr. Andrew Reaume to Board of DirectorsAugust 24, 2021 | finance.yahoo.comAdhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug CandidateAugust 2, 2021 | bizjournals.comMelior Pharmaceuticals signs multimillion-dollar licensing deal for its experimental Parkinson's disease treatmentJuly 29, 2021 | baystreet.caShares Spike On an Old Drug Being Used As a New Class of Drugs for Parkinson’s DiseaseJuly 29, 2021 | finance.yahoo.comAdhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug CandidateJune 7, 2021 | baystreet.caPharma Firm Shares Rips After Acquiring New Parkinson’s DrugJune 7, 2021 | ca.finance.yahoo.comMelior Pharmaceuticals Announces Entry Into "Letter-of-Intent" for the Acquisition of Armesocarb by Adhera TherapeuticsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRX Company Calendar Today3/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ATRX CUSIPN/A CIK737207 Webadherathera.com Phone919-518-3748Fax206-830-9424Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,350,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-863.08% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($29.65) per share Price / Book-0.02Miscellaneous Outstanding Shares3,180,000Free Float2,283,000Market Cap$1.75 million OptionableNot Optionable Beta-0.07 Key ExecutivesDr. Zahed Subhan B.S. (Age 64)BS, L.L.B., LLB (Law), M.B.A., M.S., MBA, MS, CEO, Chief Scientific Officer & Chairman Comp: $8.33kMr. Andrew Albert Kucharchuk M.B.A. (Age 41)Vice Chairman, COO, Acting CFO & Chief Bus. Officer Comp: $186kKey CompetitorsVG Life SciencesOTCMKTS:VGLSChina PharmaNYSE:CPHISunwin Stevia InternationalOTCMKTS:SUWNWellness Center USAOTCMKTS:WCUINexien BioPharmaOTCMKTS:NXENView All Competitors ATRX Stock - Frequently Asked Questions How have ATRX shares performed in 2023? Adhera Therapeutics' stock was trading at $0.82 on January 1st, 2023. Since then, ATRX stock has decreased by 32.9% and is now trading at $0.55. View the best growth stocks for 2023 here. When did Adhera Therapeutics' stock split? Shares of Adhera Therapeutics reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Adhera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced Biomedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). What is Adhera Therapeutics' stock symbol? Adhera Therapeutics trades on the OTCMKTS under the ticker symbol "ATRX." How do I buy shares of Adhera Therapeutics? Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adhera Therapeutics' stock price today? One share of ATRX stock can currently be purchased for approximately $0.55. How much money does Adhera Therapeutics make? Adhera Therapeutics (OTCMKTS:ATRX) has a market capitalization of $1.75 million. The company earns $-6,350,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. How can I contact Adhera Therapeutics? Adhera Therapeutics' mailing address is P.O. BOX 2161, WAKE FOREST NC, 27588. The official website for the company is adherathera.com. The company can be reached via phone at 919-518-3748, via email at info@adherathera.com, or via fax at 206-830-9424. This page (OTCMKTS:ATRX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.